Retroviral vector production in the National Gene Vector Laboratory at Indiana University

Gene Therapy

Volumn 12, Issue , 2005, Pages S28-S35

  Cornetta, K ^a   Matheson, L ^a   Ballas, C ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Replication competent retrovirus; Retroviral gene transfer; Vector production

Indexed keywords

LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

CELL LINE; CONFERENCE PAPER; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCREENING; TRANSGENE; VIRAL GENE THERAPY; VIRUS PURIFICATION; VIRUS RECOMBINATION; VIRUS REPLICATION;

ANIMALS; BIOTECHNOLOGY; CELL LINE; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; INDIANA; LABORATORIES; MICE; RETROVIRIDAE;

LENTIVIRUS; MURINAE;

EID: 27544432164     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302613     Document Type: Article

References (70)

1. Williams DA. Expression of introduced genetic sequences in hematopoetic cells following retroviral-mediated gene transfer. Hum Gene Ther 1990; 1: 229-239.
2. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
3. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
4. Rosenberg SA et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.
5. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159.
6. Watanabe S, Temin HM. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol 1983; 3: 2241-2249.
7. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1: 5-14.
8. Sanburn N, Cornetta K. Rapid titer determination using quantitative real-time PCR. Gene Therapy 1999; 6: 1340-1345.
9. Reeves L, Smucker P, Cornetta K. Packaging cell line charater- istics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene Ther 2000; 11: 2093-2103.
10. Kotani H et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
11. Merten OW. State-of-the-art of the production of retroviral vectors. J Gene Med 2004; 6: S105-S124.
12. Le Doux JM, Morgan JR, Snow RG, Yarmush ML. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1997; 70: 6468-6473.
13. Reeves L, Cornetta K. Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Therapy 2000; 7: 1993-1998.
14. Cornetta K. Safety aspects of human gene therapy. Br J Haematol 1992; 80: 421-426.
15. Donahue RE et al. Helper virus induction T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-1135.
16. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
17. Hacein-Bey-Abina S et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
18. Hacein-Bey-Abina S et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419 [erratum appears in Science. 2003;2302, 2568].
19. Hacein-Bey-Abina S et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
20. Berns A. Good news for gene therapy. N Engl J Med 2004; 350: 1679-1680.
21. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303: 333.
22. Muenchau DD et al. Analysis of retroviral packaging lines for generationof replication-competent virus. Virology 1990; 176: 262-265.
23. Bodine DM et al. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87: 3738-3742.
24. Scarpa M et al. Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and ampho- tropic packaging cell lines. Virology 1991; 180: 849-852.
25. Otto E et al. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum Gene Ther 1994; 5: 567-575.
26. Bosselman RA et al. Replication-defective chimeric helper proviruses and factors affecting generation of competent virus: expression of Moloney Leukemia Virus structural genes via the metallothionein promoter. Mol Cell Biol 1987; 7: 1797-1806.
27. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: seperating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124.
28. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging line. Virology 1988; 167: 400-406.
29. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotroic and ecotropic host ranges. Proc Natl Acad Sci USA 1988; 85: 6460-6464.
30. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and exprssion. BioTechniques 1989; 7: 980-990.
31. Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
32. Chong H, Starkey W, Vile RG. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol 1998; 72: 2663-2670.
33. Garrett E et al. Characterization of recombinant events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. Virology 2000; 266: 170- 179.
34. Wilson CA, Ng T, Miller AE. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors. Hum Gene Ther 1997; 8: 869-874.
35. Bassin RH et al. Normal DBA/2 mouse cells synthesize a glycoprotein which interferes with MCF virus infection. Virology 1982; 123: 139-151.
36. Cornetta K et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther 1990; 1: 13-26.
37. Cornetta K et al. Infection of human cells with murine amphotropic replication-competent retroviruses. Hum Gene Ther 1993; 4: 579-588.
38. Printz M et al. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays. Gene Therapy 1995; 2: 143-150.
39. Forestell SP, Dando JS, Bohnlein E, Rigg RJ. Improved detection of replication-competent retrovirus. J Virol Methods 1996; 60: 171- 178.
40. Miller AD et al. A novel murine retrovirus identified during testing for helper virus in human gene transfer trials. J Virol 1996; 70: 1804-1809.
41. Morgan RA, Cornetta K, Anderson WF. Application of polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells. Hum Gene Ther 1990; 1: 136-149.
42. Martineau D et al. Evaluation of PCR and ELISA assays for screening clinical trial subjects for recplication competent retrovirus. Hum Gene Ther 1997; 8: 1231-1241.
43. Long Z et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998; 20: 1165-1172.
44. Reeves L et al. Detection of ecotropic replication-competent retroviruses: comparison of S+/L— and marker rescue assays. Hum Gene Ther 2002; 13: 1783-1790.
45. Wilson C, Reitz MS, Okayama H, Eiden MV. Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of Molony Murine Leukemia Virus. J Virol 1989; 63: 2374-2378.
46. Bayle JY et al. High-efficiency gene transfer to primary monkey airway epithelial cells with retrovirus vectors using the gibbon ape leukemia virus receptor. Hum Gene Ther 1993; 4: 161-170.
47. von Kalle C et al. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 1994; 84: 2890-2897.
48. Bauer Jr TR, Miller AD, Hickstein DD. Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a Gibbon Ape leukemia virus envelope. Blood 1995; 86: 2379-2387.
49. Bunnell BA et al. High-efficiency retroviral-mediated gene transfer into human and non-human primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7739-7743.
50. Chen J, Reeves L, Cornetta K. Safety testing for replication- competent retrovirus (RCR) associated with Gibbon Ape leukemia virus pseudotyped retroviral vectors. Hum Gene Ther 2001; 12: 61-70.
51. Cosset F et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
52. DePolo NJ et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2: 218-222.
53. Sandrin V et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100: 823-832.
54. Goerner M et al. Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotyped oncoretrovirus vectors. Blood 2001; 98: 2065-2070.
55. Kelly PF et al. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96: 1206-1214.
56. Duffy L, Koop S, Fyffe J, Cornetta K. Extended S+/L— assay for detecting replication competent retroviruses (RCR) pseudotyped with the RD114 viral envelope. Preclinica 2003; May/June: 53-59.
57. Bonham L, Wolgamot G, Miller AD. Molecular cloning of Mus dunni Endogenous Virus: an unusual retrovirus in a new murine viral interference group with a wide host range. J Virol 1997; 71: 4663-4670.
58. Chen J et al. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Virology 2001; 282: 186-197.
59. Davis JL et al. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum Gene Ther 1997; 8: 1459-1467.
60. Rigg RJ et al. A novel human amphotropic packaging cell line: high titer, complement resistance and improved safety. Virology 1996; 218: 290-295.
61. Yang S et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999; 10: 123-132.
62. Ory DS, Neugeboren BA, Mulligan RC. A stable human derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G psuedotypes. Proc Natl Acad Sci USA 1996; 93: 11400-11406.
63. Yu H et al. Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 1996; 70: 4530-4537.
64. Kafri T et al. A packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584.
65. Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170-176.
66. Bowles NE et al. A simple and efficient method for concentration and purification of recombinant retrovirus for increased hepa- tocyte transduction in vivo. Hum Gene Ther 1996; 7: 1735-1742.
67. McGrath M, Witte O, Pincus T, Weissman IL. Retrovirus purification: method that conserves encelope glycoprotein and maximizes infectivity. J Virol 1978; 25: 923-927.
68. Lyddiatt A, O'Sullivan DA. Biochemical recovery and purification of gene therapy vectors. Curr Opini Biotechnol 1998; 9: 177-185.
69. Hammar L. Concentration of biomaterials: virus concentration and viral protein isolation. Meth Enzymol 1994; 228: 640-658.
70. Abonour R et al. Efficient retroviral-mediated MDR-1 gene transfer into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-658.